Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Peggy Krozely"'
Autor:
Peggy Krozely
Publikováno v:
Clinical Journal of Oncology Nursing. 8:163-168
Inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) activity have shown promise as novel anticancer agents in a variety of common solid tumors. In preclinical studies and phase I trials, tumor responses to EGFR-TK inhibitors (EGF
Autor:
Judith S. Ochs, Robert S. Smith, Barbara Pizzo, Lee M. Krug, Mark G. Kris, Peggy Krozely, Wendy Perez, Alan Sandler, Vincent A. Miller, D. P. Carbone, David H. Johnson, Leslie B. Tyson, Robert T. Heelan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(11)
Purpose: Gefitinib is an oral agent that inhibits the tyrosine kinase of the epidermal growth factor receptor. In phase I trials gefitinib was well tolerated and antitumor activity was seen in pretreated non–small-cell lung cancer (NSCLC) patients.
Autor:
Nancy Mccullough, Peggy Krozely, Jonathan E. Dowell, Russell F. DeVore, Yu Shyr, John S. Rogers, David H. Johnson
Publikováno v:
Investigational new drugs. 19(1)
Purpose: To test the efficacy and safety ofthe novel antitumor agent MGI-114 (NSC 683863) in patientswith advanced non-small cell lung cancer (NSCLC) previouslytreated with chemotherapy. Methods: A two-stageaccrual design was used to ensure detection
Autor:
K. Wyman, Mark C. Kelley, Igor Puzanov, D. Sturgeon, Peggy Krozely, Jeffrey A. Sosman, John D. Hainsworth, David R. Spigel
Publikováno v:
Journal of Clinical Oncology. 25:8539-8539
8539 Background: Erlotinib and bevacizumab have demonstrated activity in a number of malignancies by virtue of interrupting interdependent signaling pathways thought important in tumorigenesis. Melanoma may be an appropriate target based on its expre
Autor:
F. Hubbard, Peggy Krozely, V. Viar, D. Sturgeon, Jeffrey A. Sosman, Mark C. Kelley, Igor Puzanov, K. Wyman, K. Sanders
Publikováno v:
Journal of Clinical Oncology. 24:18002-18002
18002 Background: Erlotinib is a small molecule tyrosine kinase inhibitor (TKI) that targets epidermal growth factor receptor (EGFr). The EGFr is a potential therapeutic target because it is expressed by a number of malignancies, including melanocyti